Close Menu

NEW YORK – HalioDx on Tuesday announced an extended strategic collaboration with Kite Pharma aimed at developing and validating immune-based biomarkers for the drug firm's investigational therapies.

The deal covers multiple blood cancer and solid tumor indications and will leverage Marseille, France-based HalioDx's Immunoscore immune-based tests. Immunogram, the company's multiparameter approach for the analysis of the immune microenvironment of tumors, as well as HalioDx's Cancer Immune Atlas will also be used.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.